Discussion in 'Health News and Research unrelated to ME/CFS' started by Andy, Jan 3, 2020.
M.E. is to my best knowledge often associated with leaky gut. Which is why there's such an emphasis on the gut. But much more promising and measured jak-inhibitors are already in the final stages of testing(upaciditinib, filgotinib). And if I recall correctly, trials on m.e. are already underway or at least funded for those drugs.
The study talked about in the article above.
The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction
Sci hub, https://sci-hub.se/10.1093/ibd/izz266
Also see here:
Interestingly the drug, tofacitinib, is talked about in this paper.
JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis
Open access, https://onlinelibrary.wiley.com/doi/full/10.1002/art.40569
do you have a link for that information? could not find anything! ty!
Separate names with a comma.